Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
TV & Film
Sports
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts114/v4/8a/61/9e/8a619eda-4370-c5a1-6a8d-8ed30aac4c4f/mza_12824525197888336905.jpg/600x600bb.jpg
Checkpoint NOW
Afreen Shariff
32 episodes
1 week ago
All you need to know about the latest evidence based practice in the diagnosis and management of immune related toxicities from cancer therapies straight from the experts in the field.
Show more...
Medicine
Health & Fitness
RSS
All content for Checkpoint NOW is the property of Afreen Shariff and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
All you need to know about the latest evidence based practice in the diagnosis and management of immune related toxicities from cancer therapies straight from the experts in the field.
Show more...
Medicine
Health & Fitness
https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded/7711112/7711112-1605830906092-4f856047119d3.jpg
Episode 15: Neuro-toxicities from Immune checkpoint Blockade: Rare and complex (Part 1)
Checkpoint NOW
15 minutes 23 seconds
4 years ago
Episode 15: Neuro-toxicities from Immune checkpoint Blockade: Rare and complex (Part 1)

Learn from the experts about immune mediated neurological toxicities. Join our hosts Dr. Afreen Shariff and Dr. Tian Zhang as they discuss with guest expert and Neurologist Dr. Andrew Mammen. 

Andrew Mammen, M.D., Ph.D., joined NIAMS as Muscle Disease Unit Leader in the Laboratory of Muscle Stem Cells and Gene Regulation in 2014. He obtained his medical degree and Ph.D. in neuroscience at Johns Hopkins in 2000, where he subsequently completed his medicine internship, neurology residency, and neuromuscular fellowship. Prior to his appointment at NIH, he was Associate Professor of Neurology and Medicine at the Johns Hopkins University School of Medicine. He co-founded the Johns Hopkins Myositis Center in 2007, where he continues to see myositis patients as an adjunct faculty member. Dr. Mammen and his colleagues at Hopkins discovered a novel form of autoimmune myopathy associated with statin use and autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. In addition to clinical studies involving myositis patients, his current laboratory research interests include defining pathogenic mechanisms in the various forms of autoimmune myopathy and understanding the role of myositis autoantigens in muscle regeneration.

Checkpoint NOW
All you need to know about the latest evidence based practice in the diagnosis and management of immune related toxicities from cancer therapies straight from the experts in the field.